BioNTech

分析师为BioNTech股价降温：抗癌管线加速推进，但短期估值已高？

kashif hafeez - February 5, 2026

BioNTech Shifts Gears: Strategic Pivot to Oncology Gains Momentum

February 4, 2026

BioNTech股价遭遇评级下调压力

Brett Shapiro - February 4, 2026

BioNTech’s Strategic Pivot: Oncology Pipeline Gains Momentum

February 3, 2026

分析师观点现分歧，BioNTech股价涨势遇阻

Brett Shapiro - February 3, 2026

BioNTech Shares Face Headwinds Amid Strategic Shifts

February 2, 2026

BioNTech战略转型：押注肿瘤治疗新赛道

kashif hafeez - February 2, 2026

高盛看好BioNTech转型前景，上调评级至“买入”

kashif hafeez - February 1, 2026

Goldman Sachs Upgrades BioNTech, Citing Strategic Pivot to Oncology

kashif hafeez - February 1, 2026

BioNTech Shares: Consolidation Phase Precedes Potential Breakout

January 30, 2026

BioNTech战略转型迈出关键一步：高管任命与研发管线双线推进

January 30, 2026

高盛转向看多，BioNTech肿瘤战略迎来关键节点

Brett Shapiro - January 22, 2026

生物科技转型之路：押注肿瘤疗法能否开启新篇章？

kashif hafeez - January 20, 2026

生物新技术公司转型关键期：肿瘤管线能否接棒新冠疫苗收入？

Brett Shapiro - January 19, 2026

BioNTech战略转型获市场青睐，分析师上调预期至2026年

Brett Shapiro - January 18, 2026

1...8910...12 Page 9 of 12